Viridian Therapeutics (VRDN) Revenue & Revenue Breakdown

Overview ForecastOwnership Financials Chart

Viridian Therapeutics Revenue Highlights

Latest Revenue (Q)

$70.57M

Main Segment (Y)

Collaboration Revenue

Viridian Therapeutics Revenue by Period

Viridian Therapeutics Revenue by Year

Date	Revenue	Change
2024-12-31	-	-100.00%
2023-12-31	$314.00K	-82.28%
2022-12-31	$1.77M	-40.20%
2021-12-31	$2.96M	182.19%
2020-12-31	$1.05M	-76.46%
2019-12-31	$4.46M	-46.80%
2018-12-31	$8.39M	109.49%
2017-12-31	$4.00M	19.96%
2016-12-31	$3.34M	31.48%
2015-12-31	$2.54M	-41.25%
2014-12-31	$4.32M	0.08%
2013-12-31	$4.32M	-2.03%
2012-12-31	$4.41M	-

Viridian Therapeutics generated - in revenue during NA 2024, up -100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.

Viridian Therapeutics Revenue by Quarter

Date	Revenue	Change
2025-09-30	$70.57M	93993.33%
2025-06-30	$75.00K	4.17%
2025-03-31	$72.00K	-
2024-12-31	$72.00K	-16.28%
2024-09-30	$86.00K	19.44%
2024-06-30	$72.00K	-
2024-03-31	$72.00K	-
2023-12-31	$72.00K	-
2023-09-30	$72.00K	-
2023-06-30	$72.00K	-26.53%
2023-03-31	$98.00K	-6.67%
2022-12-31	$105.00K	-91.21%
2022-09-30	$1.20M	366.80%
2022-06-30	$256.00K	18.52%
2022-03-31	$216.00K	0.93%
2021-12-31	$214.00K	2.88%
2021-09-30	$208.00K	-80.92%
2021-06-30	$1.09M	-24.88%
2021-03-31	$1.45M	2587.04%
2020-12-31	$54.00K	100.00%
2020-09-30	-	-100.00%
2020-06-30	$168.00K	-79.71%
2020-03-31	$828.00K	-5.91%
2019-12-31	$880.00K	26.62%
2019-09-30	$695.00K	-72.35%
2019-06-30	$2.51M	575.81%
2019-03-31	$372.00K	-21.85%
2018-12-31	$476.00K	-49.58%
2018-09-30	$944.00K	-56.74%
2018-06-30	$2.18M	-54.39%
2018-03-31	$4.78M	301.34%
2017-12-31	$1.19M	-26.92%
2017-09-30	$1.63M	127.16%
2017-06-30	$718.00K	55.41%
2017-03-31	$462.00K	-38.89%
2016-12-31	$756.00K	-14.96%
2016-09-30	$889.00K	1.72%
2016-06-30	$874.00K	6.85%
2016-03-31	$818.00K	24.13%
2015-12-31	$659.00K	31.54%
2015-09-30	$501.00K	-31.74%
2015-06-30	$734.00K	13.80%
2015-03-31	$645.00K	-1.45%
2014-12-31	$654.52K	-49.69%
2014-09-30	$1.30M	2.15%
2014-06-30	$1.27M	16.74%
2014-03-31	$1.09M	0.03%
2013-12-31	$1.09M	10.88%
2013-09-30	$983.59K	-10.82%
2013-06-30	$1.10M	-3.20%
2013-03-31	$1.14M	-

Viridian Therapeutics generated $70.57M in revenue during Q3 2025, up 93993.33% compared to the previous quarter, and up 98013.89% compared to the same period a year ago.

Viridian Therapeutics Revenue Breakdown

Viridian Therapeutics Revenue Breakdown by Product

Annual Revenue by Product

Product/Service	Dec 24	Dec 23	Dec 22	Dec 21	Dec 20
Collaboration Revenue	$300.00K	$300.00K	$1.80M	$2.96M	$735.00K
Grant	-	-	-	-	$315.00K

Viridian Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 24: Collaboration Revenue (100.00%).

Quarterly Revenue by Product

Product/Service	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Sep 21	Jun 21	Mar 21	Dec 20	Jun 20	Mar 20
Collaboration	$570.00K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
License	$70.00M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Collaboration Revenue	-	$100.00K	$100.00K	$100.00K	$100.00K	$100.00K	-	$100.00K	$100.00K	$100.00K	$100.00K	$1.20M	$300.00K	$200.00K	$208.00K	-	-	$54.00K	-	-
Grant	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$168.00K	-
Collaboration Revenue, Related Party	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$1.09M	$1.45M	-	-	-
Reimbursement Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$700.00K

Viridian Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Sep 25: License (99.19%), and Collaboration (0.81%).

Viridian Therapeutics Peer Comparison by Revenue

Ticker	Company	Last Year Revenue	Last Quarter Revenue
RCUS	Arcus Biosciences	$258.00M	$26.00M
GLPG	Galapagos	$239.70M	$62.43M
OCUL	Ocular Therapeutix	$63.46M	$14.54M
QURE	uniQure	$27.12M	$3.70M
IBRX	ImmunityBio	$14.74M	$32.06M
CLDX	Celldex Therapeutics	$7.02M	-
GPCR	Structure Therapeutics	-	-
COGT	Cogent Biosciences	-	-
VRDN	Viridian Therapeutics	-	$70.57M
EWTX	Edgewise Therapeutics	-	-
VERA	Vera Therapeutics	-	-

VRDN Revenue FAQ

What is Viridian Therapeutics’s yearly revenue?

Viridian Therapeutics's yearly revenue for 2024 was $0, representing a decrease of -100.00% compared to 2023. The company's yearly revenue for 2023 was $314K, representing a decrease of -82.28% compared to 2022. VRDN's yearly revenue for 2022 was $1.77M, representing a decrease of -40.20% compared to 2021.

What is Viridian Therapeutics’s quarterly revenue?

Viridian Therapeutics's quarterly revenue for Q3 2025 was $70.57M, a 93993.33% increase from the previous quarter (Q2 2025), and a 81958.14% increase year-over-year (Q3 2024). The company's quarterly revenue for Q2 2025 was $75K, a 4.17% increase from the previous quarter (Q1 2025), and a 4.17% increase year-over-year (Q2 2024). VRDN's quarterly revenue for Q1 2025 was $72K, a 0% increase from the previous quarter (Q4 2024), and a 0% increase year-over-year (Q1 2024).

What is Viridian Therapeutics’s revenue growth rate?

Viridian Therapeutics's revenue growth rate for the last 3 years (2022-2024) was -100.00%, and for the last 5 years (2020-2024) was -100.00%.

What are Viridian Therapeutics’s revenue streams?

Viridian Therapeutics's revenue streams in c 24 are Collaboration Revenue

What is Viridian Therapeutics’s main source of revenue?

For the fiscal year ending Dec 24, the largest source of revenue of Viridian Therapeutics was Collaboration Revenue. This segment made a revenue of $300K, representing 100.00% of the company's total revenue.